Breast Cancer

BREAST CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

COVID-19 Vaccination and Imaging Misinterpretation: An Interview With Lacey McIntosh, DO, MPH

Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
Study Sparks Renewed Interest in Targeting Androgen Receptor in Breast Cancer

Researchers discuss the potential of enobosarm, a selective androgen receptor modulator, for the treatment of ER-positive breast cancer that has progressed on at least 1 previous endocrine therapy.
American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends

The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
PARP Inhibition Plus Macrophage-Targeting Therapy Emerges as Promising Strategy in BRCA1-Associated TNBC

This study investigates the mechanisms behind anti-CSF1R therapy and PARP inhibition’s reduction of pro-tumor macrophages in triple-negative breast cancer.
Biosimilars in Cancer Care: Insights From 2020 and Expectations for 2021

Sean McGowan, senior director of Biosimilars at AmerisourceBergen, and Brian Ansay, senior vice president of Sales and Corporate Services at ION Solutions, review 2020 biosimilar trends in oncology and forecast what is ahead in 2021.

VIDEO SERIES

The Phase 3 PlanB Trial

Continue to Work?

Drug Resistance to CDK4/6 Inhibitors

Comparing Ribociclib and Palbociclib

Ribociclib, Abemaciclib, and Palbociclib

The Potential of CDK4/6 Inhibitors

How Cyclin D Plays A Role

2016 SABCS: Clinical Insights Telli

2016 SABCS: Clinical Insights Oregan

HER2-positive Metastatic and TNBC

Frontline Treatments

Treatment-related Neuropathy

ER-positive, HER2-negative

Emerging Medicines

Triple-negative Breast Cancer

Insights from the Lab and Clinic

Trastuzumab Resistance

Biologic Role of HER2

Strategies in Management

BREAST CANCER NEWS

$The management of metastatic breast cancer resistant or refractory to hormonal treatments, while sti$

Unplanned Implant Removal Following Treatment for Locally Advanced Breast Cancer

April 15, 2021

Efficacy data from expanded access programs were reported at ASH 2020, but whether these data will inform regulatory decisions remains to be seen.

Shift to More Preoperative Therapy for Early-Stage Breast Cancer During Pandemic

April 2, 2021

The ASCO/CAP Expert Panel continues to recommend IHC as the only primary screening test for predicting benefit of endocrine therapy in breast cancer.

Effects of Treatment, Inactivity on Arm Tissue Composition in Survivors of Breast Cancer

March 29, 2021

Palbociclib with fulvestrant improved progression-free survival in hormone receptor-positive, HER2-n

Hypofractionated Whole Breast Radiation an Option in Young Women

March 23, 2021

Among patients with breast or prostate cancers, mental health conditions are associated with increas

Assessment of Tumor-Infiltrating Lymphocytes in Prognosis and Treatment Performance in Breast Cancer

March 23, 2021

Next post in Breast Cancer

Efficacy data from expanded access programs were reported at ASH 2020, but whether these data will inform regulatory decisions remains to be seen.

Shift to More Preoperative Therapy for Early-Stage Breast Cancer During Pandemic